Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + TACE with or without SBRT for hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR1900025300Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Disease remission rate. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1900025300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025300.